Literature DB >> 8306092

Suppression by intradermal administration of heparin of eosinophil accumulation but not oedema formation in inflammatory reactions in guinea-pig skin.

M M Teixeira1, P G Hellewell.   

Abstract

1. Heparin is widely used in the treatment of thrombotic disorders and as an aid in surgery. Anti-inflammatory effects of heparin have also been described. In this study, we have investigated the effects of locally-injected heparin on the oedema formation and eosinophil accumulation induced by various inflammatory stimuli in guinea-pig skin. 2. Heparin dose-dependently suppressed the accumulation of 111In-labelled eosinophils induced by i.d. injection of zymosan-activated plasma (ZAP). The 111In-eosinophil accumulation induced by other inflammatory stimuli (compound 48/80, platelet activating factor, interleukin-8 and in a passive cutaneous anaphylaxis reaction) was also suppressed by locally-injected heparin. 3. Oedema formation in response to these same stimuli was not altered by the local injection of heparin. 4. Fucoidin, a negatively-charged sulphated algal polymer, had no effect on the 111In-eosinophil accumulation or oedema formation induced by ZAP. Nevertheless, fucoidin significantly suppressed the oedema formation induced by i.d. injection of cationic protein-containing extracts of Schistosoma mansoni larvae. Heparin also inhibited oedema induced by the extracts, suggesting that both fucoidin and heparin were effectively neutralizing the cationic protein of the extracts to inhibit their oedema-inducing activity. 5. Thus, heparin significantly inhibited the accumulation of 111In-eosinophils, but not oedema formation, induced by various inflammatory stimuli. This, taken together with the lack of effect of fucoidin, suggests that heparin interferes with the process of eosinophil trafficking by a mechanism that does not depend on neutralisation of the charge of the stimulatory molecules.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8306092      PMCID: PMC2175853          DOI: 10.1111/j.1476-5381.1993.tb13991.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  39 in total

Review 1.  On scleroderma. Mast cells, endothelial cells, and fibroblasts.

Authors:  H N Claman
Journal:  JAMA       Date:  1989-09-01       Impact factor: 56.272

2.  Sulfated polysaccharides inhibit leukocyte rolling in rabbit mesentery venules.

Authors:  K Ley; M Cerrito; K E Arfors
Journal:  Am J Physiol       Date:  1991-05

3.  The accumulation of 111In-eosinophils induced by inflammatory mediators, in vivo.

Authors:  L H Faccioli; S Nourshargh; R Moqbel; F M Williams; R Sehmi; A B Kay; T J Williams
Journal:  Immunology       Date:  1991-06       Impact factor: 7.397

Review 4.  Sulfated polysaccharides in inflammation.

Authors:  K E Arfors; K Ley
Journal:  J Lab Clin Med       Date:  1993-02

5.  In vitro studies of the interaction between heparin and eosinophil cationic protein.

Authors:  K Fredens; R Dahl; P Venge
Journal:  Allergy       Date:  1991-01       Impact factor: 13.146

Review 6.  Mucosal inflammation in asthma.

Authors:  R Djukanović; W R Roche; J W Wilson; C R Beasley; O P Twentyman; R H Howarth; S T Holgate
Journal:  Am Rev Respir Dis       Date:  1990-08

Review 7.  Endothelial cell binding of NAP-1/IL-8: role in neutrophil emigration.

Authors:  A Rot
Journal:  Immunol Today       Date:  1992-08

8.  Eosinophil accumulation induced by human interleukin-8 in the guinea-pig in vivo.

Authors:  P D Collins; V B Weg; L H Faccioli; M L Watson; R Moqbel; T J Williams
Journal:  Immunology       Date:  1993-06       Impact factor: 7.397

9.  Effect of heparin, dermatan sulfate, and related oligo-derivatives on human polymorphonuclear leukocyte functions.

Authors:  G Bazzoni; A Beltrán Nuñez; G Mascellani; P Bianchini; E Dejana; A Del Maschio
Journal:  J Lab Clin Med       Date:  1993-02

10.  Inhibitory effect of fibronectin and its recombinant polypeptides on the adhesion of metastatic melanoma cells to laminin.

Authors:  I Saiki; T Makabe; J Yoneda; J Murata; Y Ishizaki; F Kimizuka; I Kato; I Azuma
Journal:  Jpn J Cancer Res       Date:  1991-10
View more
  8 in total

1.  The effects of heparin and related molecules on vascular permeability and neutrophil accumulation in rabbit skin.

Authors:  Helen Jones; William Paul; Clive P Page
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

2.  Inhibition of inflammation induced shedding of the endothelial glycocalyx with low molecular weight heparin.

Authors:  Herbert H Lipowsky; Anne Lescanic
Journal:  Microvasc Res       Date:  2017-03-27       Impact factor: 3.514

3.  Inhibitory effect of heparin-derived oligosaccharides on secretion of interleukin-4 and interleukin-5 from human peripheral blood T lymphocytes.

Authors:  Sheng-Li Ji; Hui-Fei Cui; Feng Shi; Yan-Qing Chi; Ji-Chao Cao; Mei-Yu Geng; Hua-Shi Guan
Journal:  World J Gastroenterol       Date:  2004-12-01       Impact factor: 5.742

4.  Heparin attenuates TNF-alpha induced inflammatory response through a CD11b dependent mechanism.

Authors:  A Salas; M Sans; A Soriano; J C Reverter; D C Anderson; J M Piqué; J Panés
Journal:  Gut       Date:  2000-07       Impact factor: 23.059

5.  The effects of heparin on the adhesion of human peripheral blood mononuclear cells to human stimulated umbilical vein endothelial cells.

Authors:  A Smailbegovic; R Lever; C P Page
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

6.  Size-fractionated heparins have differential effects on human neutrophil function in vitro.

Authors:  R Lever; W T Lo; M Faraidoun; V Amin; R A Brown; J Gallagher; C P Page
Journal:  Br J Pharmacol       Date:  2007-05-29       Impact factor: 8.739

Review 7.  The rationale for using low-molecular weight heparin in the therapy of symptomatic COVID-19 patients.

Authors:  Edyta Reichman-Warmusz; Oliwia Warmusz; Romuald Wojnicz
Journal:  Open Med (Wars)       Date:  2022-01-24

8.  Heparin and related drugs: beyond anticoagulant activity.

Authors:  Clive Page
Journal:  ISRN Pharmacol       Date:  2013-07-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.